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INDUCTION OF HEME OXYGENASE BY A CARBON MONOXIDERELEASING MOLECULE
By Robert Andrew Kulina
A theis submitted in partial fulfillment of the requirements for the degree of Masters of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2007
Major Director: Dorne R. Yager, Ph.D.
Associate Professor & Director of Research, Department of Plastic Surgery

We have recently demonstrated that heme oxygenase is expressed in both healing
wounds and in pressure ulcers. Heme oxygenase has been shown to have important
cytoprotective functions in myocardial ischemia-reperfusion injury and organ allograft
survival. The cytoprotective effects of heme oxygenase are multifactorial. Besides
reducing levels of pro-oxidant heme, heme oxygenase products (bilirubin, carbon
monoxide, and iron) have been demonstrated to possess anti-oxidant, anti-inflammatory,
anti-apoptotic, and anti-proliferative properties. These properties make heme oxygenase
x

xi
an attractive therapeutic target for the prevention and treatment of chronic wounds. The
purpose of this study was two-fold: evaluate the effects of carbon monoxide (CO) on the
expression of heme oxygenase (HO-1) in dermal fibroblasts, and determine and begin to
investigate the mechanisms responsible for CO-induction of HO-1. The ability of a
second-generation carbon monoxide donating molecule-tricarbonyldichlororuthenium (II)
dimer (CORM-2) to induce HO-1 protein expression in dermal fibroblasts was examined.
Western blotting techniques were utilized to determine HO-1 expression. CORM-2 (100300uM) induced maximum expression of HO-1. The maximum response to CORM-2
occurred between 12 and 20 hours. Inhibition of MAPK, PI3-K, JNK pathways showed no
changes in HO-1 expression. Likewise inhibition of cGMP, a known pathway for CO, had
no effect on protein expression suggesting that HO-1 expression by CORM-2 works by an
alternate pathway. In conclusion the ability of CO, a product of heme degradation, to
induce HO-1 in dermal fibroblasts may serve as a mechanism to amplify HO-1 expression
in stressed tissues and may serve as the basis for a novel therapeutic approach for treating
chronic wounds.

Introduction
General Purpose
Due to their complexity and multifactoral nature, little is known about chronic
wounds and the mechanisms involved in their development. Therefore current research
strategies have attempted to target various aspects of wound repair in an attempt to gain a
better understanding of the pathophysiology behind chronic wounds. One objective of this
laboratory is to determine the initiation events involved in the formation of chronic wounds
in an attempt to provide better insight for the prevention and treatment of these wounds.

Specific Aim #1: To determine if CO released from CORM-2 will alter expression of HO1 in human dermal fibroblasts

Specific Aim #2: To investigate the underlying mechanism responsible for CO induction
of HO-1 by CORM-2 in human dermal fibroblasts by identifying involved signaling
pathways. This was accomplished through the use of specific inhibitor pathways.

Hypothesis: We predicted that the carbon monoxide released from CORM-2 will inhibit
heme oxygenase expression and that the mechanism would involve the cGMP pathway.

1
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Background

Chronic skin wounds are characterized by the slow or non-healing breakdown of
epidermal and dermal tissue. Every year millions of people experience chronic wounds.26
Care of these individuals is a significant problem that will continue to grow as our
population ages. Effective wound treatment requires carefully considered interventions
often requiring multiple clinic or hospital visits which results in a significant drain on our
health system in terms of nursing time, costs, as well as physical and emotional strain to
the individual patient.14 The resulting costs of wound care are staggering and more
efficacious and cost-effective therapies are needed to decrease this burden.
The majority of chronic skin wounds are found in the lower extremities and are
predominantly due to vascular, pressure, or neuropathic (diabetic) etiology.33 The
principle population for chronic wounds is Caucasian women above the age of 65. Other
factors such as immobility, nutrition, and underlying pathogenesis (e.g. chronic venous
insufficiency and diabetes) can contribute and sometimes delay the healing process.26
Little is known about chronic wounds and the mechanisms involved in their development.
Treatments for these wounds include allografts, vacuum-closure, as well as an assortment
of topical agents and dressings.12,29 Although current treatment modalities attempt to cure
these wounds, methods to reverse the damage have proven to have modest effectiveness.
The largest obstacle is the wound tissue’s complex and multifactoral healing nature. This
characteristic has given researchers great difficulty in pinpointing the root cause for the
development and persistence of these wounds. The unique nature of each individual
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wound compounds the problem of analysis and investigation. Research efforts attempting
to examine wound pathophysiology have been hampered by the lack of an adequate
chronic wound healing model, and the complexity of the pathophysiologic wound healing
cascade has limited attempts at pharmacological modification.28 Therefore current
research strategies have attempted to target various aspects of wound repair in an attempt
to gain a better understanding of the pathophysiology behind chronic wounds.

Normal Wound Repair

Normal wound repair and regeneration is a sophisticated and highly organized
process composed of well-orchestrated interactions between a multitude of cells, chemical
pathways, and associated molecules. Individual wounds are unique; however, the steps
involved in the healing process remain the same with an end goal that results in an efficient
and predictable repair process. The entire process involves three phases or stages and can
last from several days up to a year. Although the process is separated into individual
phases, there is great overlap between them.48 The process of wound healing is very
dynamic and although the normal wound undergoes all of the phases, different parts of the
wound may be at different stages due to different healing rates.
During the first phase there is hemostasis and inflammation of the wounded area.
After the initial cut or tear in the skin, the body's priority is to stop the bleeding. This is
accomplished by the constriction of the injured endothelial cells and activation of nearby
platelets to form a clot. The clot itself is composed of platelets, fibrin, and fibronectin,
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which serve not only to attenuate bleeding but to also act as the structure upon which
migrating cells will adhere. The clot also serves to concentrate the elaborated cytokines
and growth factors.4,23 Once activated, platelets begin to secret a variety of growth factors,
cytokines, and inflammatory factors such as histamine which serve to increase blood flow
and trigger the migration of cells to the damaged area.7 The increased vasodilatation from
the buildup of cells and inflammatory factors allows for increased cellular traffic to the
area of injury. Polymorphonucleocytes (PMNs) are the primary cells that first begin to
migrate to the damaged area and enter the tissue. They are signaled to the site by
molecules such as fibronectin, growth factors, and neuropeptides.16 PMNs primary
function is to phagocytize dead and injured cells around the wound. They also secrete an
assortment of proteases that help with this function as well as to breakdown damaged
components of the extracellular matrix (ECM). These necessary processes facilitate the
fabrication/production of new extracellular matrix material. As neutrophils phagocytize
material, reactive oxygen species (ROS) are released as a by-product of their metabolism.
ROS play an important role in the wound by killing invading bacteria. After
approximately 1-2 days neutrophils die off and are replaced by vast numbers of
monocytes. Once in the tissue, monocytes differentiate into macrophages and continue to
phagocytize debris, bacteria, as well as dying neutrophils. They also trigger the release of
matrix metalloproteases (MMPs) from cells which aid in the digestion of the ECM.4
Macrophages are stimulated by the low oxygen content of their surroundings to produce
factors such as vascular endothelial growth factor (VEGF), and platelet-derived growth
factor (PDGF) which induce and speed angiogenesis.5

Macrophages also secrete a
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multitude of other chemical stimulants that cause cells to reepithelialize the wound, create
granulation tissue, and lay down a new extracellular matrix.

4,7

Stimulated fibroblasts

signal keratinocytes to migrate and proliferate. The now degraded ECM is replaced by
collagen, proteoglycans, and fibronectin. Neutrophil and macrophage numbers begin to
decrease, signaling the end of the inflammation phase and the start of the proliferation
phase.
The proliferation phase is characterized by matrix formation, proliferation of
fibroblasts, and increased migration of endothelial cells. Fibroblast and endothelial cells
are the dominant cells during this phase. Epithelialization occurs soon after the initial
injury. This proliferation is triggered by EGF and TGF-α released from platelets and
macrophages.17 Fibroblasts stimulated by TGF-β produce and begin secreting fibrin,
fibronectin, collagen, as well as other molecules to form the new ECM. This newly
formed ECM will also act as a lattice upon which cells can adhere. TGF- β causes
fibroblasts to differentiate into myofibroblasts which aid in wound contraction.10 As
collagen and other components of the ECM are laid down, the final phase of wound repair
begins.
The last phase, maturation and remodeling, is characterized by the depositing of
collagen in such a fashion as to make an organized matrix. This matrix continues to
become thicker and stronger as more collagen is deposited. During this time levels of
MMPs as well as other proteases, that were once utilized to breakdown the previous
matrix, are decreasing. Abnormalities in this last phase can result in clinical disorders such
as the development of keloids or hypertrophic scars.4,53 In the later stages of healing, the
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high density of capillaries, myofibroblasts and the hypertrophic epidermal layer undergo
apoptosis (programmed cell death), effectively thinning the tissue and returning it to a
normal appearance.4,7,9

Impaired Wound Healing

Normal wound repair is an organized and predictable process that involves a
precise balance between the breakdown of damaged tissue and production of new tissue
that results in the timely healing of the wound. For one reason or another, nonhealing
chronic wounds have lost this balance and organization and are detained in one or more of
the wound healing stages. These wounds may take months, years, or never heal at all.
There are various types of chronic wounds each with unique characteristics. The majority
of chronic wounds can be classified into three categories composed of: pressure ulcers,
venous ulcers, and diabetic foot ulcers.26
Accounting for more than 70 to 80% of all cases, venous ulcers are the most
prevalent type of chronic wound. There are approximately 600,000 reported cases each
year in the US alone.15,26 Although the precise etiology of these wounds is not known,
these ulcers occur almost exclusively in association with chronic venous insufficiency
(CVI) in the lower extremities, where they are characterized by substantial and prolonged
venous hypertension.36 Venous hypertension is most often a result of damaged or nonfunctioning valves that fail to prevent the backflow of blood. This pooling of the blood at
high pressure in the lower-extremities leads to of tissue hypoxia, necrosis, and ultimately
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ulceration. Other condition such as cutaneous arteriovenous fistulas, thrombosis, and
leukocyte-plugging can compound the problem by further depriving the already hypoxic
skin.35,38,54 Research has also demonstrated that hypertension, circulatory stasis, and
blood-shearing forces can trigger an increased inflammatory response, which is thought to
contribute to ulcer development.38 Compression therapy is utilized to encourage the flow
of nutrients as well as to prevent venous stasis, edema, and blood clot formation.
Pressure ulcers constitute another important class of chronic wounds. Localized
damage to the skin and underlying tissue from pressure, shear, or frictional forces result in
the formation of these wounds. Typically 95% of these lesions occur in the lower
extremities in which tissue over a bony prominence such as the sacrum or the heel is thin
and hypoxia is more likely to occur.50 The majority of these wounds are found in elderly
patients (>65) and are associated with co-morbid conditions such as poor nutrition and
immobility.26 These wounds are readily observed in hospitals and nursing homes where
patient mobility might be a challenge. Prolonged pressure to a site leads to the occlusion
of capillary and lymphatic vessels which impedes the flow of blood and lymph resulting in
tissue ischemia. Eventually, these changes coupled with reperfusion injury lead to necrosis
of the underlying muscle, tissue, dermis and epidermis.50 If no corrective action is taken,
tissue pressure can reach 200mmHg expediting ulcer formation.11 Prevention and
treatment of these wounds is difficult, and once wounds form , they are a clinical challenge
to treat. This is especially true in paralyzed and other immobile patients. Pressure wounds
take time to develop. By the time external symptoms are noted, severe underlying tissue
damage has already occurred.
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The third and final class of chronic wounds is the diabetic foot ulcer. The
incidence of this class of wound has increased as the prevalence of diabetes has risen over
that past decade. Diabetic foot problems occur in both type 1 and type 2 diabetes and are
most common in men (>65).14,41 Like pressure ulcers, diabetic ulcers usually occur around
the heel region of the foot and can be a result of prolonged pressure. Infection has been
one of the major obstacles in treatment of these wounds. If not treated immediately
infection can result in the amputation of the limb and sometimes death. Chronic foot
ulceration is the leading cause of amputation in the elderly patient population,39 with
diabetics having a 15-fold higher incidence of amputation compared to nondiabetics.32
Neuropathy associated with diabetes also affects detection and treatment. With a higher
threshold of pain and sensation, these patients become unaware of ischemic pain and
pressure ulcer formation. Both this reduced perception of pain and sensation combined
with an already weakened immune system increases the risk of infection. As the disease
progresses a weakened immune system can also cause damage to small blood vessels,
preventing adequate oxygenation of tissue, which can exacerbate chronic wounds.30
Immobility, structural deformity, and peripheral vascular diseases associated with diabetes
all lead to ulcer formation. Due to the many disease conditions and problems associated
with diabetes, there is great difficulty in the prevention and treatment of these wounds.

Common Factors
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Research has had little success in determining the etiology of chronic wounds. The
multifactoral nature coupled with the uniqueness of each individual wound has proven to
be a major obstacle. Although each class of chronic wounds appears to have little in
common, there are some similarities between the groups. Age, tissue hypoxia, ischemiareperfusion injury, and bacterial colonization all seem to be major players in the wound
formation and maintenance. As noted, the majority of chronic wounds occur in elderly
patients over the age of 65.34 Cells in the local environment of a chronic wound are subject
to significant stresses, including chronic inflammation, the harmful presence of reactive
oxygen species, ischemia-reperfusion injury, as well as an increase of various proteases in
their environment. These stresses act to prolong healing time and have been shown to alter
gene expression. Studies have shown that in addition to these stresses, aged patients also
have an increased rate of cell senescence and a decreased proliferative capacity.33 As
mentioned above other factors such as immobility, impaired or weakened immune systems
as well as a number of other diseases common among elderly contribute to wound
development and risk of infection thus decreasing the body’s ability to heal efficiently.
Adequate perfusion of the skin and tissue is very important for normal wound
healing. Tissue oxygenation is regulated by blood flow which is in turn controlled by
arterial flow, arteriovenous gradients, capillary density, and local tissue metabolism.34
Lack of sufficient oxygen supply to the site is predominantly due to edema. By increasing
actual tissue pressure and the distance between tissue and capillaries, edema reduces the
diffusion of oxygen resulting in a hypoxic state. Edema is readily found in diabetic foot
ulcers as well as pressure and venous ulcers although not as common.38,41
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Another similarity is the invasion of bacteria into the injured area. Within 48 hours
of injury, bacteria from the surrounding skin invade the site resulting in a baseline level of
bacteria.3 Inflammation is triggered as the immune system responds to the invading
bacteria thereby adding stress to an already compromised environment. Protease levels
and inflammatory molecules increase as the number of migrating neutrophils rise. These
proteases begin to degrade growth factors and parts of the ECM necessary for proper
healing. The type and amount of bacteria also seem to be important in wound
development and maintenance. Skin grafts performed on wounds with bacterial counts in
excess of 100,000/mm3 have had little success.42 Treatments such as vacuum-assisted
closure have had moderate success partly because it is believed that it reduces the bacterial
count.3,42
Ischemia-reperfusion injury (I/R) is the last factor associated with all three classes
of chronic wounds. Although the etiology of each type of chronic wound is difficult to
pinpoint, recent research hypothesis’ that I/R injury is the key event common in the
formation of all three types of wounds.33,40 I/R injury has also been linked in the
pathophysiology of other diseases such as myocardial infarction, cerebral ischemia, stroke,
hemorrhagic shock, and organ transplantation.1
I/R injury occurs when blood supply to tissue is interrupted resulting in ischemia
thereby damaging metabolically active tissue. Restoration of blood flow to the ischemic
area initiates a cascade of events that can act to potentiate cell injury. In venous stasis
ulcers, the lack of an arterial-venous pressure gradient results in the pooling of blood in the
lower extremities. This blood stasis prevents the flow of nutrients and oxygen to
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surrounding tissue and eventually leads to ischemic injury. When the leg is elevated or
moved, flow is restored resulting in reperfusion injury. In diabetic ulcers and pressure
wounds ischemia result from pressure on the tissue over protruding bony areas such as the
heal or sacral area. When the pressure is removed reperfusion injury occurs.34 The
repetitive nature of I/R injury makes it so damaging. Each cycle acts to further injure the
already damage area and will eventually cause tissue necrosis and ulcer formation.
Inflammation and reactive oxygen species (ROS) are the key mechanisms
responsible for the damaging affects of I/R injury. As ischemia in tissue intensifies, lack
of oxygen and vital nutrients dramatically alter the ability of cells to perform aerobic
metabolism. As a result surrounding tissue reduces its metabolism in order to maintain
function and soon glycolysis becomes the predominant source of ATP.21 Anaerobic
metabolism results in a dramatic decrease in ATP levels and the cell cannot sustain the
transmembrane potential across the plasma membrane. Disruption of this potential results
in the influx of various ions (mainly Na+), which cause the cell to swell. ATP-independent
pumps such as the Na+/Ca2+ exchanger are activated to help reestablish normal ion
concentrations and to prevent cell lysis. Intracellular Ca2+ levels rise and trigger pathways
that lead to membrane breakdown as well as activation of reactive oxygen species.24,51
Ischemia also induces the expression of endothelial adhesion molecules and
cytokines that serve to create a pro-inflammatory environment. As ischemia ends and
reperfusion begins, leukocytes migrate into the ischemic area and attach themselves to the
wall of the endothelium as well as to each other. These interactions are mediated through a
series of glycoproteins, mainly selectins and integrins. Once attached, the leukocytes
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begin to interact with the inflammatory cytokines and mediators already produced by the
ROS to form tight interactions with the endothelium. Mediated by cell adhesion molecules
(like P-selectin, L-selectin, PAF, E-selectin, IL-8, VCAM, and B2-integrins), leukocytes
start their migration into the tissue.45 Once in the tissue leukocytes such as PMNs and
macrophages cause damage by secreting proteases as well as producing large amounts of
ROS and may even obstruct surrounding microcirculation further contributing to an
already ischemic environment.19 A decrease in nitric oxide (NO) is also associated with
I/R injury. Less nitric oxide significantly impairs reperfusion and is responsible for
signaling the increased production of proteases and pro-inflammatory cytokines.20
Reactive oxygen species (ROS) describes oxygen free radicals such as superoxide
(O2-), hydroxyl radical (OH-) as well as nonradical oxygen species like hydrogen peroxide
(H2O2). In moderate concentrations, these species play an important role in the wound
healing process serving as cellular messengers.19 However in excess, these species can
have a variety of harmful effects on both the cellular and tissue level. The majority of
reactive oxygen species are produced by neutrophils during the ‘respiratory burst’ phase of
inflammation, however macrophages, fibroblasts, and endothelial cells produce them as
well.56 ROS can have a wide variety of damaging effects on proteins, membrane lipids,
and nucleic acid in DNA. Oxidation of proteins is primarily through the hydroxyl radical
and most readily affects sulfhydryl groups. This modification can alter protein structure
and function and can lead to increased proteolytic turnover.19 Changes in the proteolytic
environment can result in defective or insufficient ECM formation leading to prolonged
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healing. Not only do ROS play a significant role in chronic wounds but they also have
been implicated in other skin diseases, including skin cancer and psoriasis.31

Heme Oxygenase

As local tissue undergoes repeated bouts of ischemia followed by reperfusion, red
blood cells and tissue begin to breakdown. One consequence of RBC destruction is the
release of heme into the bloodstream. Free heme can interact with oxygen to produce
cytotoxic ROS, which can ultimately cause DNA damage, lipid peroxidation, and protein
degradation.22 The body counteracts the harmful effects of free heme by producing the
enzyme heme oxygenase.
Heme oxygenase catalyzes the first and rate-limiting step in the oxidative
degradation of heme to carbon monoxide, biliverdin, and free iron (Fe2+) (Figure 1).
Researchers have characterized two main isoforms of heme oxygenase; an inducible
isoform, heme oxygenase-1 (HO-1), and a constitutively expressed isoform, heme
oxygenase-2 (HO-2). Recently there has also been some debate over a third possible
isoform.25 The two main isoforms catalyze the same reaction and are very similar in
structure, sharing a 43% amino acid homology. Both HO-1 and HO-2 also have similar
enzyme kinetics with HO-1 having a slightly greater affinity for the heme molecule.43
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Figure 1: Heme oxygenase and its byproducts: biliverdin, bilirubin, Fe2+, and CO.
Ryter, S. W. et al. Physiol. Rev. 86: 583-650 2006; doi:10.1152/physrev.00011.

15
HO-1 (~32 kDa), the main isoform, is omnipresent throughout the body with higher
concentrations located in areas with high RBC and hemoglobin turnover including the
spleen, liver, kidney, and bone marrow. Subcellularly, HO-1 is distributed in the
endoplasmic reticulum, nucleus, and plasma membrane. HO-2 (~36 kDa) is distributed in
the liver, spleen, brain and testes with similar subcellular locations as HO-1.37,43
Originally discovered and categorized as a class of heat shock proteins (Hsp32),
heme oxygenase functions in the protection against cellular stresses. Unlike HO-2, which
is constituently expressed, the inducible form of heme oxygenase (HO-1) remains at
relatively undetectable levels until expression is triggered by cellular stresses.43 HO-1
responds to a multitude of chemical and physical stressors including hypoxia, ROS, UV
irradiation, quinones, nitric oxide, heavy metals, cytokines (TNF-α, interleukins, TGF-β),
lipopolysaccharide and, organic chemicals (e.g. sodium arsenite).2,8 Multiple factors are
responsible for the induction of heme oxygenase underlying its importance as a protective
mechanism throughout the body.
The cytoprotective effects of heme oxygenase are multifactoral. Besides reducing
levels of pro-oxidant heme, HO-1 products (bilirubin, carbon monoxide, and iron) have
been demonstrated to possess anti-oxidant, anti-inflammatory, and anti-apoptotic
properties.43 Iron (Fe2+) is one of the first of three products resulting from the catabolism
of heme. Most of the cytoprotection afforded by Fe2+ is believed to be linked to its ability
to increase the expression of the protein ferritin. Ferritin primarily functions in the
maintenance of normal concentrations of cellular iron. In vitro experiments have also
determined that iron helps to maintain intracellular iron concentrations through the
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activation of a series of ATP-dependent iron pumps. By binding iron, ferritin also prevents
free iron from stimulating reactive oxygen species formation.
Biliverdin is another product formed from the breakdown of heme. Almost
immediately after formation biliverdin is converted to bilirubin by the enzyme biliverdin
reductase. Both biliverdin and bilirubin have been demonstrated to possess anti-oxidant
effects.43 In vitro experiments have demonstrated bilirubin’s ability to prevent the
photoxidation of hydrocarbons by complexing with singlet molecular oxygen. Other
studies have shown that bilirubin protects cells by neutralizing harmful agents such as
hypochlorous acid released from macrophages.37,43
Once thought of as deleterious or at best as waste, carbon monoxide has recently
attracted interest by its beneficial effects. Like oxygen, carbon monoxide has the ability to
reversibly bind to hemoglobin and myoglobin. With an affinity approximately 240 times
that of oxygen, carbon monoxide preferentially binds to the active sites of hemoglobin.43
Carbon monoxide concentrations above physiological levels will result in hypoxia and
destruction of oxygen sensitive vital organs including the brain and lungs. If levels remain
high, CO poisoning will eventually lead to respiratory distress and death. In contrast to
high levels of CO, lower levels have been demonstrated to possess cytoprotective effects.
One of the major effects of CO is its role in inflammation. Carbon monoxide prevents the
activation and aggregation of platelets; thereby reducing the ability of platelets to produce
and release pro-inflammatory signals. Another protective function of CO is its ability to
inhibit apoptosis in certain cells including endothelial, fibroblasts, hepatocytes, and β-cells
of the pancreas.18,37,43
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HO-1 derived CO apparently operates through multiple pathways, each unique to
different types of cells. The two main pathways identified to date, involve the activation of
the mitogen activated protein kinases (MAPK) and cyclic guanylyl cyclase (cGMP)
systems.

Carbon monoxide can bind directly with soluble guanylyl cyclase (sGC)

thereby stimulating the production of cGMP. Cyclic GMP can then directly perform its
effects on the target cells. Treatment with YC-1 (a sGC agonist) increases the sensitivity
of sGC stimulation by CO.43 In contrast, signaling of p38 MAPK by CO is not as direct as
the cGMP pathway. The MAPK pathway represents the downstream target rather than the
direct binding target for CO.44 The primary binding target of CO for activation of this
pathway is unknown and may differ for each cell type. The target for CO may also involve
several different molecules. Other potential targets of CO include proteins in which heme
acts as a prosthetic group (e.g. hemoglobin, myoglobin, sGC, cyclooxygenase, cytochrome
p450 oxidase, iNOS, and NADPH) as well as proteins that have metal ions (e.g. Zn, Cu,
Mn, Fe) incorporated into their structure.43

Carbon Monoxide Releasing Molecules (CORMs)

One of the limitations in studying carbon monoxide has been its delivery to the
target. The majority of in vitro experiments rely on the perfusion of CO for the treatment
of cells. Recent work by Motterlini et al. however; has led to the development of
molecules that can spontaneously release CO. Carbon monoxide releasing molecules
(CORMs) are a set of carbonyl compounds containing a central metal ion (i.e. Mn, B, Ru,
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Fe) designed for the release of CO in tissues.43 Four types of CORMs (CORM-1, -1A, -2,
and -3) have been developed each with the same function, however differing slightly in
their structure, solubility and release kinetics. The prototype CORM-1 (Mn2(CO)10) was
very constrained in its requirement for photoactivation to release CO.43 Other problems
arose from its hydrophobic nature, limiting solubility in aqueous media. CORM-2 is the
second generation of CORMs to be developed.

This molecule possesses a ruthenium core

and was hydrophobic like its predecessor. However unlike CORM-1, CORM-2 is able to
release CO in an organic solvent depending on ligand displacement by the solvent (i.e.
DMSO). The latest forms, CORM-3 and CORM-1A, are the most refined and are more
compatible with biological systems. Both are water-soluble and release CO by exchanging
CO for water. Limitations of CORM-3 include its extremely rapid release and half-life of
CO; while CORM-1A’s rate of CO release is dependent on pH changes.13,43 Due to its
relatively recent development, current research surrounding the use of CORMs is very
limited. Studies have shown that CORM-2 possesses anti-inflammatory effects in mouse
lung and human colonic epithelial cells. These studies suggest that CORM-2 exerts its
effect through NF-κB and MAPK pathways.27,49 In conclusion, these molecules provide a
novel approach for the application of CO into biological systems and may provide another
therapeutic approach to vascular dysfunction, inflammation, tissue ischemia and organ
rejection.
The goal of this study was to determine whether carbon monoxide, a product of
heme oxygenase-mediated degradation of heme, could influence the expression of heme
oxygenase-1 in human dermal fibroblasts. At present, there are no studies that have
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examined whether any heme oxygenase products can feedback modulate the expression of
this enzyme. In addition, the expression and regulation of HO-1 in human dermal
fibroblasts has not been examined in any detail. Human dermal fibroblasts play a pivotal
role in the wound healing and remodeling process. Therefore, modulation of the expression
of HO-1 by fibroblasts may represent a novel approach for the treatment of problematic
wounds.

Materials and Methods

Cells/ Tissue Culture

Human dermal fibroblasts derived from neonatal skin were utilized for these
studies. These fibroblasts have been selected because of the ready availability of neonatal
skin and cells derived from these tissues demonstrate less variability than those derived
from the adult skin. The cells utilized were from low passage numbers (no more than 10).
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with
10% fetal calf serum, 100 U penicillin per ml, and 100mg streptomycin per ml under 5%
CO2 and at 37°C. Cells were passaged (1:2) immediately upon becoming confluent.

Harvesting Cells/ Protein Extraction

After treatment and incubation, media was aspirated from the 100mm cell plates.
Approximately 10ml of 1X PBS was added to the dish and the cells were scraped. The
cell/ PBS mixture was then transferred to a centrifuge tube and pelleted by centrifugation
at 1000 x g for 5 minutes at 4°C. The PBS was then discarded and the cells were lysed in
50-100ul of 0.2% SDS-50mM Tris pH 6.8-1mM PMSF. Cells were then sonicated for 3-5
20
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seconds to disrupt chromatin. Lysates were clarified by centrifugation (15,000 x g for 10
minutes at 4°C). Lysates were stored at -80°C until use.

Harvesting Cells/ RNA Extraction

After treatment, media was removed from the cell plates. Cells were scraped up
into 10ml of ice-cold 1X PBS. The cell and PBS mixture was then transferred to a test
tube and pelleted by centrifugation at 1000 x g for 5 minutes at 4°C. The PBS was then
discarded and the cells lysed in 1ml of Tri-reagent. The mixture was pipetted up and down
vigorously to ensure shearing of DNA and then transferred to a new tube. After transfer,
approximately 200μl of CHCl3 was added. The mixture was then vortexed and centrifuged
at 15,000 x g for 15 minutes at 4°C to separate the phases. The aqueous layer was then
transferred to a new tube. An equal amount of isopropanol was added and the nucleic acid
collected by centrifugation at 15,000 x g for 15 minutes at 4°C. The isopropanol was then
removed leaving the pellet inside the tube. To remove residual DNA and carbohydrates,
1ml of 2M LiCl (DEPC-treated) was added to the pellet and the solution was vortexed and
centrifuged (15 x g 15 minutes at 4°C). The LiCl was then removed and the pellet was
then washed with 70% ethanol. After removing the final ethanol wash, the RNA was
suspended in approximately 25μl of DEPC-treated H2O. Yields of RNA were calculated
using Beer’s law:
A=eCl
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where A is the measured absorption at 260 nm, e is the RNA extinction coefficient (25 μl /
μg / cm), C the RNA concentration and l is the pathlength (1 cm). Rearrangement of this
equation yields:
C = A / (e l) = A * 40 μg/ml
The actual RNA concentration C(sample) = C(meas) * dilution factor. Approximately
50µg of total RNA was a typical yield from a 100mm dish. The RNA was then stored at
-80°C until intended use.

CORM-2 Treatments: Dose Response

Tricarbonyldichlororuthenium(II) dimer( FW 512) (CORM-2) was used as a source
for CO. CORM-2 was dissolved in DMSO to a concentration of 300mM (153 mg/ml).
Previous research has shown heavy metals to induce the expression of heme oxygenase.43
Therefore, a control consisting of ruthenium chloride in DMSO was included in most
experiments. Due to the relatively short half-life of CORM-2 in DMSO (t1/2=~20 min).
Care was taken to rapidly serially dilute (half-log dilutions) the CORM-2 after initially
suspending it in DMSO. Five 1.5ml tubes were each filled with 400ul of DMSO. Serial
dilutions were made by transferring and mixing 200μl (100, 30, 10, 3mM) into the tubes
containing 400μl DMSO. 10μl each of 300, 100, 30, 10, 3mM CORM-2 solutions were
added to separate plates for a final concentration of 300, 100, 30, 10, 3μM CORM-2 (0.1%
DMSO). Plates were then placed back into the incubator. After approximately 16-20
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hours the cells were harvested using the aforementioned protocol. Immunodetection of
HO-1 was performed utilizing Western Blotting techniques.

CORM-2 Treatments: Time Course

Eleven confluent plates (100mm) were prepared for each time (0, 15, 30, 45min,
and 1, 2, 4, 8 , 12, 24, 48 hours). CORM-2 was dissolved into DMSO to make a 100mM
(51mg/ml) concentration. 10μl of 100mM CORM-2 was rapidly added to each plate for a
final concentration of 100μM. The plates were then placed back into the incubator until
they were harvested. Each plate was harvested at a different time corresponding to 0, 15,
30, 45min, and 1, 2, 4, 8, 12, 24, 48 hours time points. Immunodetection of HO-1 was
performed utilizing Western Blotting techniques.

Inhibitor Experiments

Eleven confluent cell plates (100mm) were prepared for this experiment. Inhibitors
for the JNK, PI3K, MAPK, cGMP, tyrosine kinase, and PKC pathways were utilized
(Table 1). Previous research in our laboratory has demonstrated the effectiveness of these
inhibitors in human dermal fibroblasts. The inhibitor IC50 values were tripled to produce
an inhibitor concentration that insured blockage of the pathway (Table 2). First each
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inhibitor plate was pretreated with the specific inhibitor for approximately 2-3 hours. This
allowed the inhibitors to begin working before the CORM-2 was added. After
pretreatment, approximately 50-100mg of CORM-2 was weighed out and dissolved into
DMSO to make a 100mM (51mg/ml) concentration. Since the half-life of the CORM-2 is
so short (approximately 20 min) it is important to quickly perform the next few steps. The
CORM-2 was then rapidly suspended into DMSO to 100mM. 10μl of 100mM CORM-2
was added to each of the inhibitor plates for a final concentration of 100μM. CORM-2
was also added to one other plate as a CORM-2 only control. Other controls included a
DMSO plate, a 100μM RUCL plate, a no treatment plate, and a reverse order CORM-2
plate. The reverse order CORM-2 was prepared by driving out the CO in the CORM-2
solution by bubbling nitrogen for 10 seconds. After treatment the plates were then placed
back into the incubator until they were harvested. Immunodetection of HO-1 was
performed utilizing Western Blotting techniques.
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Table 1: Inhibitor treatments.
Plate

Treatment
Final Conc.
1 No treatment
2 DMSO treated
3 Reverse Order
4 RuCl
100uM
5 CORM-2 only 100uM
6 ODQ
20nM
7 U0126
250nM
8 LY294002
4.2uM
9 SB202190
1uM
10 SP600125
300nM
11 Herbimycin A 2700nM
12 Calphostin C 150nM
13 Genistein
7.8uM

Pretreatment CORM-2 applied

x
x
x
x
x
x
x
x

x
x
x
x
x
x
x
x
x

Table 2: Agonist and inhibitors utilized. (Calbiochem)
Inhibitor Name
ODQ
U0126
LY294002
SB202190
SP600125
Herbimycin A
Calphostin C
Genistein

Pathway
cGMP
Mek/Mapk
PI3K
p38/Mapk
JNK-2
Tyr Kinase
PKC
Tyr Kinase

Agonist Name
YC-1
cGMP

IC50
20nM
72nM
1.4uM
280nM
90nM
900nM
50nM
2.6uM

300nM
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Micro-BCA Protein Assay

Protein concentrations of samples were measured utilizing the Pierce MicroBicinchoninic acid (BCA) protein assay kit according to Smith et al.46 The peptide bonds
of protein interact with alkaline Cu2+ to form a tetradentate- Cu1+ complex. Bicinchoninic
acid is a water-soluble sodium salt that binds to the cuprous (Cu1+) ion to form a purple
color.46 Greater protein concentrations in the sample result in a proportionally more
intense purple color. 3μl of the protein sample and 97μl dH2O were pipetted into a 96
well dish for a volume of 100μl. Bovine Serum Albumin (BSA) (1mg/ml) was used as the
protein for the standards. The concentrations of BSA gradually increased from well one
(no BSA) to well eight (24μl BSA). The standards were prepared by first pipetting
decreasing volumes of dH2O into 8 wells (97, 95, 93, 89, 85, 81, 77, 73μl). Next
increasing volumes of BSA were added to each of the standard wells except the first one
(0, 2, 4, 8, 12, 16, 20, 24μl). 3μl of vehicle was then added to each of the standard wells
for a final volume of 100μl. Vehicle represents the buffer/solution in which the protein
sample is harvested and stored. Most cell lysis buffers contain detergents that can alter the
color response of this assay. To compensate for this, equivalent amounts of the solution
that the sample is in were added to the BSA standards. 100μl of working reagent was
added to the standards and samples for a final volume of 200μl. Each well was mixed and
the bubbles were removed from each well. Wells containing protein will develop a purple
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color. A Bio-Tek plate reader at a wavelength of 562nm then read the absorbance for
approximately 20-30 minutes. It may be necessary to develop for a longer period for more
dilute samples. Concentrations and standard curves were then calculated and analyzed.

Immunodetection of Heme Oxygenase

After protein concentrations were determined using the BCA assay, Western
Blotting techniques were utilized for the immunodetection of HO-1. Approximately 60ug
of protein sample was diluted in dH2O for a volume of 30ul. To this, 6μl of reducing
Laemmli buffer (as above, but with 900mM 1,4-dithiothreitol) was added. Samples were
heated for five minutes at 95°C, loaded onto a 10% SDS-PAGE gel, and then run at 150 V
for approximately one hour. After electrophoresis the gel was transferred to nitrocellulose
or PVDF (Polyvinylidene Fluoride Transfer Membrane) membrane based on the Towbin
method.52 Ten ml of 10x electroblot buffer (250mM Tris, 1.92M Glycine) was diluted
with deionized water to a 1x solution. The transfer cassette and nitrocellulose were
assembled while submerged in a pyrex dish containing the electroblot buffer to avoid
trapping bubbles in the cassette. Buffer was poured into an electrophoresis chamber along
with a cooling insert, a small stirring bar, and the cassette. The apparatus was mounted on
a magnetic stirrer to facilitate buffer circulation, and transfer was initiated at maximum
current (400mA, Bio-Rad Power Pac 300) for approximately one hour. The apparatus was
removed and the gel was traced along the nitrocellulose with a soft #2 pencil. Pre-stained
markers were also outlined.
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The nitrocellulose was then set for immunodetection. The membrane was placed in
20ml TBST blocking solution (20mM Tris, 137mM NaCl, 0.1%Tween, pH to 7.6 with
HCl) containing 5% nonfat dried milk, positioned on a rocking table, and incubated at
room temperature for 3 hours. Primary antibodies (Rabbit Anti-HO-1 Polyclonal,
Stressgen) were diluted 1000:1 in 20ml of TBST containing 1% BSA, then applied to
membranes and incubated overnight with rocking at 4°C. Primary solution was then
removed and the membranes were washed four times with 30ml of TBST for 10 minutes
each. The secondary antibody (Anti-Rabbit IgG horseradish peroxidase-linked,
Amersham) was diluted 10,000:1 in 20 ml of TBST and applied to the gels, incubating at
room temperature with rocking for one hour. The solution was discarded and the
membranes washed four times in TBST for 10 minutes each. During the final wash,
equivalent amounts (5ml each) of Enhanced Luminol Reagent and Oxidizing Reagent
(Western Lighting Chemiluminescence Reagent Plus, PerkinElmer Life Sciences) were
prepared. Membranes were placed in chemiluminescent reagent for 1 minute each, then
wrapped in Saran Wrap (Kroger, OH) and sealed. In the darkroom, several exposures were
made at varying durations (1”, 10”, 60”) on Kodak X-Omat AR film.

Cyclic GMP experiment
Six confluent cell plates were prepared for this experiment. The first three plates
served as the controls for this experiment (Plate one was not treated, plate two was DMSO
treated, and plate three was CORM-2 only.)
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1. Control: no treatment
2. DMSO only
3. CORM-2 only
4. CORM-2 and YC-1
5. CORM-2, YC-1 and ODQ
6. CORM-2 and ODQ

First the cGMP inhibitor (ODQ) was diluted to a concentration of 20μM (3X IC50). The
cGMP agonist (YC-1, Calbiochem) was then diluted to 300nM. Plates #3, 4, 5 were
pretreated for 2-3 hours with inhibitor, agonist, or inhibitor and agonist. After
pretreatment, approximately 50-100mg of CORM-2 was weighed out and dissolved into
DMSO to make a 100mM (51mg/ml) concentration. The CORM-2 was then rapidly
suspended into DMSO to 100mM. 10μl of 100mM CORM-2 was then added to plates #2,
3, 4, and 5. DMSO was then added to plate six. After treatment the plates were then
placed back into the incubator until they were harvested. Immunodetection of HO-1 was
performed utilizing Western Blotting techniques.

Statistical Analysis
Western blot images were scanned with SigmaScan software and densitometrically scored.
Values were recorded and presented as functions of volume, which was computed as
average intensity x area of the protein bands.

Results
BCA assay/ Protein Quantification
The standard curves for all protein samples were very accurate. Each assay
produced an R2 value of .95 or greater (perfect score when R2 =1). As a result we were
confident of the amount and concentration of our protein samples. Protein concentrations
usually ranged from 3 to 10μg/μl depending on the amount of buffer added to the protein
in the last step of harvesting.
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A.

B.

Figure 2. Standard curves generated for A) dose response and B) time-course
experiments.
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HO-1 Immunoblots

1. Dose Response

The purpose of this experiment was to determine if CORM-2 would induce heme
oxygenase as well as to determine which CORM-2 concentration would produce the
strongest expression. Western blot analysis demonstrated that incubation with CORM-2
induced the expression of heme oxygenase-1. Different concentrations of CORM-2 (0, 10,
30, 100, 300μM) were correlated with increased expression of heme oxygenase-1. The
peak HO-1 expression occurred at 100μM and began to decrease at larger concentrations.
Previous research has shown heavy metals to induce the expression heme oxygenase.43
Therefore, a control consisting of ruthenium chloride in DMSO was included in most
experiments. A DMSO only treated plate served as another control. Controls did not
induce HO-1 expression.
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Figure 3. Carbon Monoxide induced heme oxygenase-1 expression in dermal fibroblasts.
Fibroblasts were incubated with different concentrations of carbon monoxide donor,
CORM-2. After approximately 16 hours, HO-1 expression was assessed by immunoblot
analysis. Lanes: 1) untreated cells; 2) DMSO only; 3) 100μM Ruthenium(III) chloride
hydrate; 4-7) 10, 30, 100, 300μM CORM-2.
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2. Time-course

The purpose of this experiment was to determine the time response of HO-1 to
CORM-2 induction. From the previous dose response assay, it was determined that
maximum HO-1 expression occurred with 100μM CORM-2. Western blot analysis
demonstrated that heme oxygenase-1 expression increased gradually over time. It was
determined that heme oxygenase expression peaked around 16 hours. Longer treatments
resulted in decreased expression. Controls, ruthenium(III) chloride hydrate and DMSO
treated cells, failed to induce HO-1.
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Figure 4. Time-course induction of heme oxygenase-1 by CORM-2. Fibroblasts were
incubated with 100μM CORM-2. Samples were harvested at different time points ranging
from 0 minutes to 48 hours. Once harvested, HO-1 expression was assessed by
immunoblot analysis. Lanes: 1) 0 min; 2) 15 min; 3) 30 min; 4) 45 min; 5-11) 1, ,2 , 4, 8,
12, 24, 48 hr respectively.
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3. Inhibitor experiments

The purpose of this experiment was to identify the mechanism for the induction of
HO-1 by CORM-2. Well-characterized inhibitors of various signaling pathways were used
(Table 1). These include an inhibitor of ERK (U0126 ); p38 (SB202190 )(Cells were
pretreated with a three-fold higher concentration of the reported IC50 for each inhibitor.
Cells pretreated with inhibitors for JNK-2, p38/p42/MEK MAPK, PI3K, cGMP pathways
resulted in no change of heme oxygenase-1 expression after treatment with CORM-2.
Inhibition of PKC and tyrosine kinase pathways by calphostin C, genistein, and
herbimycin A did not alter expression.
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Inhibitors

Figure 5. Effect of JNK-2, PI3K, p38/ MEK MAPK, cGMP inhibitors on CO induction of
HO-1 in dermal fibroblasts. Fibroblasts were pretreated for 2-3 hours with inhibitors and
then treated with 100μM CORM-2 (lanes 1-5, 7, and 9). After approximately 16 hours,
cells were harvested and HO-1 expression was assessed utilizing immunoblot analysis.
Lanes: 1) LY294002 (3μM); 2) SB202190 (1μM); 3) SP600125 (300nM); 4) U0126
(260μM); 5) ODQ (20μM); 6) DMSO only; 7) untreated cells; 8) CORM-2 only; 9)
Ruthenium(III) chloride hydrate (100μM).
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Figure 6. Effect of PKC and Tyrosine kinase inhibitors on CO induction of HO-1 in
dermal fibroblasts. Fibroblasts were pretreated for 2-3 hours with inhibitors and then
treated with 100μM CORM-2 (lanes1-4). After approximately 16 hours, cells were
harvested and HO-1 expression was assessed utilizing immunoblot analysis. Lanes: 1)
Genistein (7.8nM); 2) Calphostin C (150nM); 3) Herbimycin A (2.7μM); 4) 100μM
CORM-2 only; 5) Ruthenium Chloride hydrate (100μM); 6) DMSO only; 7) untreated
cells.
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4. Cyclic GMP

The purpose of this experiment was to determine if a cGMP agonist would induce
HO-1. Western blot analysis demonstrated that treatment of fibroblasts with ODQ, a
cGMP inhibitor, did not block or attenuate HO-1 expression. It was also shown that
treatment with YC-1, a cGMP agonist, did not turn on HO-1. These data suggest that COinduction of heme oxygenase-1 by CORM-2 operates through a pathway that is
independent of cGMP.
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Figure 7. Cyclic GMP did not induce heme oxygenase-1 expression in dermal fibroblasts.
Fibroblasts were pretreated with YC-1 and ODQ, a cGMP agonist and inhibitor, and then
incubated with CORM-2. After approximately 16 hours, cells were harvested and HO-1
expression was assessed utilizing immunoblot analysis. Lanes: 1) CORM-2 only; 2)
untreated cells; 3) DMSO only; 4) CORM-2 and YC-1; 5) YC-1 only; 6) CORM-2 and
ODQ.
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mechanism for the prevention of heme depletion. We initially speculated that in similarly
dermal-derived fibroblasts, CO would act as a feedback inhibitor of HO-1 expression.
However, data obtained in this study provide a strong indication that CO released via
CORM-2 is an efficient inducer of HO-1 expression.

The absence of a similar induction

using ruthenium chloride or DMSO only suggests that this response is likely due to that of
CO and not to the heavy metal moiety of the tricarbonyldichlororuthenium(II) dimer or to
the DMSO vehicle. Whether CO supplied as a gas elicits the same response remains to be
tested.
Dose response experiments revealed that CORM-2 CO induced the expression of
HO-1 with maximum expression occurring at 100µM. Time-course experiments revealed
that maximum HO-1 expression occurred between 12 and 24 hours after treatment with
100μM CORM-2.
Our next aim was to begin identifying the signaling pathway or pathways involved
in CO induction of HO-1. Other studies have indicated that CO exerts its effects through a
multitude of pathways, with MAPK and soluble guanylyl cyclase (sGC) being the
predominant cascades (Figure 8).43 As a result, it was our hypothesis that the CO released
from CORM-2 would most likely act through one of these major pathways. To test this
hypothesis, inhibitor experiments were conducted. Inhibitors utilized included those for
sGC, MAPK (p38, JNK-II, ERK) pathways as well as those for tyrosine kinase, and PKC
cascades. Pretreatment with inhibitors permitted sufficient time for the inhibitors to enter
the cells.

Inhibitor concentrations applied to the cells were triple the IC50 to increase the

likelihood of inhibition without inducing undue secondary inhibition of other kinases or
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causing unacceptable levels of cell death. Somewhat surprisingly, our data suggests no
relationship between these pathways and induction of HO-1 by CORM-2. Controls for this
experiment included untreated, DMSO, and RuCl treated plates. These controls showed no
increase in HO-1 expression.
Because much of the literature supports a role for guanylate cyclase mediating CO
signaling, the ability of a cGMP agonist43, YC-1, to induce the expression of HO-1 was
tested. YC-1 treated cells did not show any significant induction of HO-1 protein.
Blockage of the cGMP pathway also did not attenuate CO-induction of HO-1. These
results support the previous data indicating that CORM-2 operates through a cGMPindependent pathway. Interestingly, cells treated with ODQ and CORM-2 seemed to
potentiate HO-1 expression. Similar results were reported in experiments with CORM-3
and ODQ in human platelets.6 This suggests that the action of CO might be accentuated
by the removal of the sGC function. The mechanism and physiological meaning of these
findings remain to be determined.
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Figure 8. Signaling pathways for carbon monoxide.
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Future Perspectives
It seems unlikely that gaseous CO and CO released from CORM-2 are chemically
distinct entities. Therefore the most plausible explanation is that the CO released from
CORM-2 reaches different targets. Apart from the pathways tested, other studies have
demonstrated that CO can act through the modulation of NF-kappaB/IkB molecules.27,49
Therefore blockage of this pathway might provide some insight into the mechanism
responsible for the induction of HO-1 by CORM-2. CO has a high affinity and readily
binds to metal ions.43 Therefore binding of CO to the metal ions present in some proteins
might be another mechanism by which HO-1 is induced. In our experiments we utilized
the second-generation CORM-2 molecule that incorporates the heavy metal ruthenium into
its structure. Although the ruthenium chloride control did not show an increase in HO-1
expression, future studies should utilize CORM-1A. Use of this molecule would
effectively reduce the chance that the effects of CORM-2 on HO-1 expression are a result
of heavy metal stimulation. CORM-1A is also more soluble in aqueous environments
allowing for more efficient diffusion of CO into the media and onto the cells.
Although the exact mechanism remains to be elucidated, the results of this study
may have important implications. It is surprising that CO, a product of heme degradation,
released from CORM-2 actually increases the expression of HO-1 in human dermal
fibroblasts. This may serve as a mechanism to amplify heme oxygenase expression in
stressed tissue. In contrast to higher levels, lower levels of CO possess beneficial
characteristics. In certain epithelial cell lines and in models for post-ischemic myocardial
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injury, CORMs have already been demonstrated to show beneficial characteristics.27,55 As
a result, there might be possible therapeutic applications of CORM-2 due to its induction
of HO-1 and associated cytoprotective effects. CORMs may provide a method by which
local application may be beneficial as opposed to systemic CO which is harmful.
Although a significant amount of research has been performed on chronic wounds,
we still have very limited understanding of the pathophysiology behind the development
and maintenance of these lesions. Therefore by elucidating the mechanism by which HO-1
is expressed in these cells, future research might be able to develop more effective
therapeutic approaches for the treatment of chronic wounds.
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